Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Explore the unique financial literacy challenges women face and how to overcome them. Empower your financial journey with vital insights.
28,655 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Bitcoin briefly climbs above $81,000 as on-chain profits hit a cycle high, prompting traders to weigh the risk of a s...
India tightened gold import rules this week, a move officials say protects the rupee, but traders warn it could bolst...
DeepSeek just secured its first outside investment from a state-backed fund, marking a turning point in China’s AI fu...
A top AI stock is flirting with a $1.6 trillion market value as optimism for AI-driven growth runs hot. Yet traders a...
CONY’s eye-popping payouts mask a much steeper NAV decline. A 37% drop since inception signals a structural risk behi...
Bridgewater Associates exits its Salesforce stake, prompting a broader discussion on how patient capital should value...
A new income-focused ETF challenger has pushed past JEPI by roughly 42 percentage points since its October 2023 debut...
Amazon’s Q1 2026 results show AWS posting rapid growth amid a surge in AI demand. With AI revenue above $15B and a $2...
A closer look at JEPQ reveals a persistent gap between monthly income and total returns. The premium income ETF pays ...
A fresh market screen identifies five high-yield dividend stocks trading under $10, presenting a potential income lif...
Michael Burry’s shorts going strong have produced noticeable gains in select AI-adjacent bets, prompting a timely deb...